Menovag

Estradiol, the active ingredient in Menovag, is an estrogen presented as a vaginal formulation for local use. It is employed to restore estrogenic activity in post‑menopausal women, helping to alleviate systemic menopausal symptoms and to treat urogenital atrophy of the vaginal tissues.

GNH USA supplies Menovag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled batches that meet European Union regulatory standards.

Menovag (estradiol) acts on estrogen‑dependent pathways to address conditions associated with estrogen deficiency.

- Menopausal symptoms: reduction of hot flashes, night sweats and mood disturbances. - Vaginal atrophy: restoration of vaginal epithelium, decreasing dryness and discomfort. - Urogenital atrophy: improvement of urinary irritation and frequency related to estrogen loss.

Adverse reactions may occur with vaginal estradiol therapy.

Common Side Effects: - Vaginal irritation or burning sensation. - Increased vaginal discharge or spotting. - Mild headache. - Breast tenderness. - Nausea. - Itching of the genital area.

Serious or Rare Side Effects: - Unexplained vaginal bleeding. - Thromboembolic events (deep vein thrombosis, pulmonary embolism). - Endometrial hyperplasia or carcinoma. - Severe allergic reaction (rash, swelling, difficulty breathing).

Use of Menovag requires careful assessment of patient history and monitoring.

- Assess contraindications: history of estrogen‑dependent neoplasia or thromboembolic disease. - Monitor for signs of vaginal bleeding or abnormal discharge. - Evaluate liver function in patients with hepatic impairment. - Consider cardiovascular risk factors, especially in older women. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Estradiol may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Combined hormonal contraceptives: increased risk of thromboembolism. - Systemic estrogen therapy: additive estrogenic effects. - Anticoagulants: potential alteration of clotting parameters. - Tamoxifen: antagonistic effect on estrogen receptors.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: may affect estradiol metabolism. - Antifungal azoles (e.g., ketoconazole): may increase estradiol plasma levels. - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may reduce estradiol effectiveness.